Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
1 paper2 findings
- 1 lab in 1 country
- Funder: Fundação de Amparo à Pesquisa do Estado de São Paulo
- Humans1
Outcomes
1Dialysis initiation
downin humans1
1 study
Dialysis initiation
downin humans1
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker decreases dialysis initiation in humans (P = .005).
“Patients using angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI-ARB) had a lower probability of requiring dialysis (P = .005) and a lower probability of death (P = .005).”
Humansstage 4-5 CKDmedian 1.8 yearsn = 150
Age and ageing1 Feb 2026
Associations
1Mortality
downin humans1
1 study
Mortality
downin humans1
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker lowers the risk of mortality in humans (P = .005).
“Patients using angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI-ARB) had a lower probability of requiring dialysis (P = .005) and a lower probability of death (P = .005).”
Humansstage 4-5 CKDmedian 1.8 yearsn = 150
Age and ageing1 Feb 2026
Latest
1 in 12 monthsAge and Ageing
AGNES-AGing NEphropathy study-a prospective cohort of older patients with advanced chronic kidney disease
Cohort study of 150 peopleChronic kidney disease